会長講演 神経変性疾患の分子標的治療を目指して
スポンサーリンク
概要
- 論文の詳細を見る
Although recent advancements in molecular biology have provided increasing insights into the pathophysiology of neurodegenerative diseases, there is almost no disease-modifying therapy for which the efficacy has been verified in clinical trials. Spinal and bulbar muscular atrophy (SBMA) is an adult-onset motor neuron disease caused by the expansion of a trinucleotide CAG repeat in the androgen receptor (AR) gene. SBMA exclusively affects males, whereas does not manifest in the females homozygous for the AR mutation. The ligand-dependent nuclear accumulation of pathogenic AR protein is central to the pathogenesis, although additional steps such as inter- and intra-molecular interaction are also required for toxicity. Leuprorelin, a luteinizing hormone-releasing hormone (LHRH) analogue that suppresses testosterone production from testis, inhibits toxic accumulation of pathogenic AR, thereby mitigating histopathological and behavioral impairments in a mouse model of SBMA. Although a randomized placebo-controlled multi-centric clinical trial showed no definite effect of the drug on motor functions, there was the improvement of swallowing function in a subgroup of patients whose disease duration was less than 10 years. These results indicate a need to elucidate the entire disease mechanism, clarify the natural history, initiate therapeutic intervention at an early stage, and develop sensitive outcome measures to evaluate drug effect.
- 日本神経学会の論文
日本神経学会 | 論文
- 書字動作の神経科学 : 書字運動の計算理論モデルを中心に
- 重症筋無力症に合併した難治性バセドウ眼症の1例
- 神経サルコイドーシスの診断基準案
- 大腸癌とその転移にともなう凝固線溶系の異常により脊髄円錐部出血をきたした1例
- 垂直性共同視麻痺を呈した両側延髄内側梗塞の1例